Qim­ing, Hill­house bet on Ja­co­bio's nascent pipeline of first-in-class drug hope­fuls in $55M round

Qim­ing Cap­i­tal and Hill­house Cap­i­tal are bet­ting on a Chi­nese biotech to de­liv­er world-class in­no­va­tion in their lat­est in­vest­ment.

Aside from the two promi­nent VCs, Ja­co­bio has al­so at­tract­ed Hong Kong-based Pru­dence In­vest­ment Man­age­ment in the $55 mil­lion Se­ries C.

While many of Chi­na’s more well-known biotechs have a mix of li­censed and in-house prod­ucts in their pipeline, Bei­jing-based Ja­co­bio firm­ly po­si­tioned it­self in nov­el drug R&D, set­ting up a sub­sidiary and a joint ven­ture to ful­ly flesh out its treat­ments for can­cer, au­toim­mune and in­fec­tious dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER